Under the Paperwork Reduction Act of 1995, no persons are requir a collection of information unless it contains a valid CMB control number.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		
Filing Date		
First Named Inventor	Jan l	B. M. WARNTJES
Art Unit		
Examiner Name		-
Attorney Docket Numb	er	PHNL040245US

				U.S.	PATENTS		Remove	
Examiner Initial*	r Cite No Patent Number		Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines who Relevant Passages or Re Figures Appear		
	1	4786871		1988-11-22	Hoshino	all		
	2	5107215		1992-04-21	Schaefer, et al.	all		
	3	5416412		1995-05-16	Slayman, et al.	all		
	4	6522141	B2	2003-02-18	Debbins, et al.	all		
	5	6687527	B1	2004-02-03	Wu, et al.	all		
If you wis	h to a	dd additional U.S. Paten	t citatio	n information p	lease click the Add button.		Add	
			U.S.P	ATENT APPLI	CATION PUBLICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document Pages, Columns, Li Relevant Passage Figures Appear		Lines where ges or Relevan	
	1	20020067165	A1	2002-06-06	Rabe, et al.	all		

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		
iling Date		
First Named Inventor Jan 8		B. M. WARNTJES
Art Unit		
Examiner Name		
Attorney Docket Number		PHNL040245US

	2	20020087066	A1	2002-07	7-04	Hellinger		all			
If you wish to add additional U.S. Published Application citation information please click the Add button. Add											
FOREIGN PATENT DOCUMENTS Remove											
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code4	Publication Date	Name of Patentee Applicant of cited Document		where Rel	or Relevant	Ţ5
	1	JP 5176911	JP		A	1993-07-20	Hitachi Medical		all		
If you wis	h to a	dd additional Foreign P	atent Do	cument	citation	information pl	ease click the Add	buttor	Add		
			NON	I-PATEN	NT LITE	RATURE DO	CUMENTS		Remove		
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journat, seriat, symposium, catalog, etc), date, pages(s), volume-issue number(s),								T5		
	1 SIVALINGAM, B. et al., improvement of SNR for Knee Imaging Using SENSE; 2003; Proc. Intl. Soc. Mag. Reson. [										
	WEIGER, M., et al.; increasing the SNR in Steady-State Imaging by Sensitivity Encoding; 2001; Proc. Intl. Soc. Mag. Reson. Med; 9: pp. 1798										
If you wish	h to a	dd additional non-paten	t literatu	re docur	ment cit	ation informati	on please click the	Add b	utton Ad	d	
EXAMINER SIGNATURE											
Examiner	Examiner Signature Date Considered										
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a											

See find. Code of USPTO Planto Documents at year, USPTO, COV or MPEP 901.04. \* Enter office that sweet the document, by the low-lefter code (WIPO) Standard ST3.3.\* \* Fraginese plant documents, the includion to the year of the reging or the Emperor mant processor the senior increase for the plant document. \* Mind of coursent by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \* Applicant is to plant a check mark here if Employin tanguage streamlisten as standard.

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

# Application Number Fing Date Fing Date Fing Date Fing Total Fing Total Find T

### CERTIFICATION STATEMENT

Diagra can	37	CER	1	Q7 and	10	8 to	make	the	appropriate	coloction/c	· Ye

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(eVI).

## OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no term of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1/5(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/3/(c)(d).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Thomas M. Lundin/	Date (YYYY-MM-DD)	2006-09-05								
Name/Print	Thomas M. Lundin	Registration Number	48979								

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, U.S. operationed for Commence, P. 0. Bot 1450, Alexandria, V.S. 2213.1-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.2313.1-1450.

# Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually intermediate or for extension or about those when the basic high process another examines your submission, which may visually intermediate or for extension or a submission of the basic high process another examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandomed or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.